{"protocolSection": {"identificationModule": {"nctId": "NCT01192152", "orgStudyIdInfo": {"id": "CV181-112"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 \u00d7 500 mg Glucophage XR", "officialTitle": "Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 \u00d7 500 mg Glucophage XR Coadministered to Healthy Subjects in the Fed State and Steady State Pharmacokinetic Assessment of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-11"}, "primaryCompletionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-08-30", "studyFirstSubmitQcDate": "2010-08-30", "studyFirstPostDateStruct": {"date": "2010-08-31", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-03-09", "resultsFirstSubmitQcDate": "2011-04-19", "resultsFirstPostDateStruct": {"date": "2011-05-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-04-22", "lastUpdatePostDateStruct": {"date": "2015-05-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to demonstrate bioequivalence (BE) of a 5 mg saxagliptin/1000 mg metformin extended release (XR) fixed-dose combination (FDC) tablet (manufactured in Mt Vernon, Indiana) relative to a coadministered 5 mg Onglyza tablet (saxagliptin, manufactured in Mt Vernon, Indiana) and two 500 mg Glucophage XR tablets (metformin XR, manufactured in Evansville, Indiana) in the fed state in healthy subjects.", "detailedDescription": "This study is designed to evaluate if the FDC tablet of 5 mg saxagliptin/1000 mg metformin extended release (manufactured in Mt Vernon, Indiana) is bioequivalent to the coadministered 5 mg saxagliptin tablet plus 2 x 500 mg Glucophage XR tablets (manufactured in Evansville, Indiana)"}, "conditionsModule": {"conditions": ["Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 30, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "5 mg saxagliptin + 2 Glucophage XR 500 mg tablet", "type": "EXPERIMENTAL", "interventionNames": ["Drug: saxagliptin", "Drug: Glucophage XR"]}, {"label": "FDC tablet (5 mg saxa + 1000 mg metformin XR) (single dose)", "type": "EXPERIMENTAL", "description": "under fed state, single dose", "interventionNames": ["Drug: saxagliptin + metformin XR (FDC tablet)"]}, {"label": "FDC tablet (5 mg saxa + 1000 mg metformin XR) (4 days)", "type": "EXPERIMENTAL", "description": "under fed state, 4 days", "interventionNames": ["Drug: saxagliptin + metformin XR (FDC tablet)"]}], "interventions": [{"type": "DRUG", "name": "saxagliptin", "description": "Tablets, Oral, 5 mg, once daily, Single dose", "armGroupLabels": ["5 mg saxagliptin + 2 Glucophage XR 500 mg tablet"], "otherNames": ["Onglyza"]}, {"type": "DRUG", "name": "Glucophage XR", "description": "Tablets, Oral, 500 mg, once daily, Single dose", "armGroupLabels": ["5 mg saxagliptin + 2 Glucophage XR 500 mg tablet"]}, {"type": "DRUG", "name": "saxagliptin + metformin XR (FDC tablet)", "description": "Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days", "armGroupLabels": ["FDC tablet (5 mg saxa + 1000 mg metformin XR) (4 days)", "FDC tablet (5 mg saxa + 1000 mg metformin XR) (single dose)"], "otherNames": ["Onglyza"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])", "timeFrame": "Periods 1 and 2: pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing."}, {"measure": "Saxagliptin Observed Maximum Plasma Concentration (Cmax)", "timeFrame": "Periods 1 & 2: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 & 48 hrs post-dosing. Period 3: predosing on Days 2 & 3; predosing, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hrs postdosing on Day 4"}, {"measure": "Metformin AUC(0-inf)", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing."}, {"measure": "Metformin Cmax", "timeFrame": "Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4."}], "secondaryOutcomes": [{"measure": "Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])", "timeFrame": "Periods 1 and 2: pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing."}, {"measure": "Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC[0-tau])", "description": "Dosing interval = 24 hours.", "timeFrame": "Period 3: pre-dosing on Days 2 and 3; pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours post-dosing on Day 4."}, {"measure": "Saxagliptin Trough (Predose) Plasma Concentration (Cmin)", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4."}, {"measure": "Saxagliptin Average Plasma Concentration Over the Dosing Period (Cavg)", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4."}, {"measure": "Saxagliptin Degree of Fluctuation Over the Dosing Interval (Fluctuation %)", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4."}, {"measure": "Saxagliptin Terminal Half-life (T1/2)", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing."}, {"measure": "Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing."}, {"measure": "Saxagliptin Time to Achieve the Observed Maximum Plasma Concentration (Tmax)", "timeFrame": "Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4."}, {"measure": "5-hydroxy Saxagliptin AUC(0-inf)", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing."}, {"measure": "5-hydroxy Saxagliptin AUC(0-t)", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing."}, {"measure": "5-hydroxy Saxagliptin AUC(0-tau)", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4."}, {"measure": "5-hydroxy Saxagliptin Cmax", "timeFrame": "Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4."}, {"measure": "5-hydroxy Saxagliptin Cmin", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4."}, {"measure": "5-hydroxy Saxagliptin Cavg", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4."}, {"measure": "5-hydroxy Saxagliptin Fluctuation %", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4."}, {"measure": "5-hydroxy Saxagliptin T1/2", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing."}, {"measure": "5-hydroxy Saxagliptin AUC(0-t)/AUC(0-inf)", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing."}, {"measure": "5-hydroxy Saxagliptin Tmax", "timeFrame": "Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4."}, {"measure": "Metformin AUC(0-t)", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing."}, {"measure": "Metformin AUC(0-tau)", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4."}, {"measure": "Metformin Cmin", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4."}, {"measure": "Metformin Cavg", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4."}, {"measure": "Metformin Fluctuation %", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4."}, {"measure": "Metformin T1/2", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing."}, {"measure": "Metformin AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing."}, {"measure": "Metformin Tmax", "timeFrame": "Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4."}, {"measure": "Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)", "description": "AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.", "timeFrame": "AEs: from initiation of study drug administration on morning of Day 1/Period 1 through study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or participation in study if last scheduled visit occurred later."}, {"measure": "Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities", "description": "Abnormalities considered clinically significant and/or reported as an AE by the investigator.", "timeFrame": "From Day 1 of Period 1 to Day 3 of Period 2 for participants in Treatment Sequence BA and Day 5 of Period 3 for participants in Treatment Sequence ABC"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy male and female subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations\n* Body Mass Index (BMI) of 18 to 32 kg/m\u00b2, inclusive\n* Ages 18 to 55, inclusive\n\nExclusion Criteria:\n\n* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population\n* Major surgical procedure within 4 weeks prior to randomization\n* Positive serology test for HIV, HBV or HCV\n* Clinically significant history or presence of any of the following conditions: heart, liver, or kidney disease, neurologic or psychiatric disease\n* History of gastrointestinal disease within the past 3 months\n* Any clinically significant medical condition that could potentially affect your participation in the study and/or personal well-being, as judged by the investigator\n* Donated blood or blood products to a blood bank, blood transfusion or participated in a clinical study (except a screening visit) requiring withdrawal of blood within 4 weeks prior to randomization\n* Unable to tolerate oral and/or intravenous (IV) medications\n* Unable to tolerate the puncturing of veins for drawing of blood\n* Known allergy or hypersensitivity to any component of the study medication\n* History of any significant drug allergies (such as anaphylaxis or hepatotoxicity)\n* Used any prescription drugs or over the counter products to control acid (for example, Prevacid, Mylanta or Rolaids) within 4 weeks prior to randomization\n* Used any other drugs including over the counter medications and herbal preparations within 1 week prior to randomization\n* Taken any investigational drug or placebo (inactive drug) within 4 weeks prior to randomization", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "45 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "PPD Development, LP", "city": "Austin", "state": "Texas", "zip": "78744", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}]}, "referencesModule": {"references": [{"pmid": "21819160", "type": "DERIVED", "citation": "Boulton DW, Smith CH, Li L, Huang J, Tang A, LaCreta FP. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects. Clin Drug Investig. 2011;31(9):619-30. doi: 10.2165/11590290-000000000-00000."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants underwent screening evaluations to determine eligibility within 21 days before dosing, and were admitted to the clinical facility the evening before dosing (Day -1). On Day 1 of Period 1, a total of 30 participants who met all of the inclusion and none of the exclusion criteria were randomly assigned to 1 of 2 treatment sequences.", "groups": [{"id": "FG000", "title": "Treatment Sequence ABC", "description": "Treatment A (period 1): 5 mg saxagliptin + 2 Glucophage XR 500 mg under fed conditions; Treatment B (period 2):Fixed dose combination (FDC) tablet (5 mg saxa + 1000 mg metformin XR), single dose, under fed conditions; Treatment C (period 3): FDC tablet (5 mg saxa + 1000 mg metformin XR), once daily for 4 days, under fed conditions. Participants underwent a 2-day washout period between Periods 1 and 2. There was no washout between Periods 2 and 3."}, {"id": "FG001", "title": "Treatment Sequence BA", "description": "Treatment B (period 1):Fixed dose combination (FDC) tablet (5 mg saxa + 1000 mg metformin XR), single dose, under fed conditions; Treatment A (period 2): 5 mg saxagliptin + 2 Glucophage XR 500 mg under fed conditions. Participants underwent a 2-day washout period between Periods 1 and 2."}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "left prematurely (while on treatment B)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "14"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "family emergency", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Enrolled and Treated Participants"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "30"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.6", "spread": "7.76"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "17"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "13"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "17"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "166.85", "spread": "9.02"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "71.56", "spread": "9.39"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "25.69", "spread": "2.70"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])", "populationDescription": "All treated participants not discontinuing prior to the end of study. One participant in Treatment A was excluded as a result of the inability to estimate with acceptable accuracy a terminal slope for the terminal phase concentration data. Treatment C was administered only during Period 3, and this outcome measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1 and 2: pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "99.45", "spread": "18.34"}, {"groupId": "OG001", "value": "105.28", "spread": "23.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of a 5-mg saxagliptin tablet plus two 500-mg metformin XR tablets under fed conditions, then 24 subjects would have provided 99% power to conclude bioequivalence (BE) with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided 94% and 99% power to conclude BE with respect to Cmax and AUC0-inf.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within 0.800 to 1.250 for both Cmax and AUC0-inf of saxagliptin.", "paramType": "Ratio of geometric least squares means", "paramValue": "1.045", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.025", "ciUpperLimit": "1.065", "estimateComment": "Ratio = Treatment B/Treatment A. Geometric least squares means values presented in other statistical analysis entries."}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares means for Treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "103.05", "ciPctValue": "95"}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares means for Treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "98.61", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])", "populationDescription": "All treated participants not discontinuing prior to end of study. Treatment C was administered only during Period 3, and this outcome measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1 and 2: pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "97.76", "spread": "17.96"}, {"groupId": "OG001", "value": "103.34", "spread": "22.73"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Ratio of geometric least squares means", "paramValue": "1.035", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.009", "ciUpperLimit": "1.062", "estimateComment": "Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares means for Treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "101.16", "ciPctValue": "95"}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares means for Treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "97.72", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 to the End of the Dosing Interval (AUC[0-tau])", "description": "Dosing interval = 24 hours.", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Period 3: pre-dosing on Days 2 and 3; pre-dosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours post-dosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "19.20", "spread": "20.68"}]}]}]}, {"type": "PRIMARY", "title": "Saxagliptin Observed Maximum Plasma Concentration (Cmax)", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Periods 1 & 2: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 & 48 hrs post-dosing. Period 3: predosing on Days 2 & 3; predosing, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hrs postdosing on Day 4", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25.28", "spread": "6.40"}, {"groupId": "OG001", "value": "25.75", "spread": "6.92"}, {"groupId": "OG002", "value": "25.75", "spread": "7.13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of saxagliptin from the FDC tablet versus saxagliptin from coadministration of a 5-mg saxagliptin tablet plus two 500-mg metformin XR tablets under fed conditions, then 24 subjects would have provided 99% power to conclude bioequivalence (BE) with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided 94% and 99% power to conclude BE with respect to Cmax and AUC0-inf.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within 0.800 to 1.250 for both Cmax and AUC0-inf of saxagliptin.", "paramType": "Ratio of geometric least squares mean", "paramValue": "0.999", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.948", "ciUpperLimit": "1.053", "estimateComment": "Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares means for Treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "24.85", "ciPctValue": "95"}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares means for Treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "24.88", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Saxagliptin Trough (Predose) Plasma Concentration (Cmin)", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "0.28", "spread": "0.10"}]}]}]}, {"type": "SECONDARY", "title": "Saxagliptin Average Plasma Concentration Over the Dosing Period (Cavg)", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "4.13", "spread": "0.86"}]}]}]}, {"type": "SECONDARY", "title": "Saxagliptin Degree of Fluctuation Over the Dosing Interval (Fluctuation %)", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of fluctuation", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "611.85", "spread": "107.36"}]}]}]}, {"type": "SECONDARY", "title": "Saxagliptin Terminal Half-life (T1/2)", "populationDescription": "All treated participants not discontinuing prior to the end of study. One participant in Treatment A was excluded as a result of the inability to estimate with acceptable accuracy a terminal slope for the terminal phase concentration data. Treatment C was administered only during Period 3, and this outcome measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.69", "spread": "3.71"}, {"groupId": "OG001", "value": "8.85", "spread": "4.47"}]}]}]}, {"type": "SECONDARY", "title": "Saxagliptin Fraction of AUC(0-inf) Contributed by AUC(0-t) (AUC[0-t]/AUC[0-inf])", "populationDescription": "All treated participants not discontinuing prior to the end of study. One participant in Treatment A was excluded as a result of the inability to estimate with acceptable accuracy a terminal slope for the terminal phase concentration data. Treatment C was administered only during Period 3, and this outcome measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.981", "spread": "0.010"}, {"groupId": "OG001", "value": "0.982", "spread": "0.008"}]}]}]}, {"type": "SECONDARY", "title": "Saxagliptin Time to Achieve the Observed Maximum Plasma Concentration (Tmax)", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hour", "timeFrame": "Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.88", "spread": "0.87"}, {"groupId": "OG001", "value": "1.51", "spread": "0.64"}, {"groupId": "OG002", "value": "1.35", "spread": "0.51"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin AUC(0-inf)", "populationDescription": "All treated participants not discontinuing prior to the end of study. One participant in Treatment A was excluded as a result of the inability to estimate with acceptable accuracy a terminal slope for the terminal phase concentration data. Treatment C was administered only during Period 3, and this outcome measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "298.80", "spread": "69.32"}, {"groupId": "OG001", "value": "296.99", "spread": "69.35"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin AUC(0-t)", "populationDescription": "All treated participants not discontinuing prior to end of study. Treatment C was administered only during Period 3, and this outcome measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "293.06", "spread": "68.28"}, {"groupId": "OG001", "value": "289.37", "spread": "68.72"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin AUC(0-tau)", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "318.47", "spread": "54.95"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin Cmax", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54.69", "spread": "17.00"}, {"groupId": "OG001", "value": "51.32", "spread": "16.19"}, {"groupId": "OG002", "value": "59.87", "spread": "13.83"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin Cmin", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "1.51", "spread": "0.22"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin Cavg", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "13.27", "spread": "2.29"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin Fluctuation %", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of fluctuation", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "437.09", "spread": "43.97"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin T1/2", "populationDescription": "All treated participants not discontinuing prior to the end of study. One participant in Treatment A was excluded as a result of the inability to estimate with acceptable accuracy a terminal slope for the terminal phase concentration data. Treatment C was administered only during Period 3, and this outcome measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours post-dosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.48", "spread": "1.78"}, {"groupId": "OG001", "value": "13.82", "spread": "2.52"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin AUC(0-t)/AUC(0-inf)", "populationDescription": "All treated participants not discontinuing prior to the end of study. One participant in Treatment A was excluded as a result of the inability to estimate with acceptable accuracy a terminal slope for the terminal phase concentration data. Treatment C was administered only during Period 3, and this outcome measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.975", "spread": "0.009"}, {"groupId": "OG001", "value": "0.973", "spread": "0.010"}]}]}]}, {"type": "SECONDARY", "title": "5-hydroxy Saxagliptin Tmax", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hour", "timeFrame": "Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.69", "spread": "0.80"}, {"groupId": "OG001", "value": "2.27", "spread": "0.84"}, {"groupId": "OG002", "value": "2.05", "spread": "0.57"}]}]}]}, {"type": "PRIMARY", "title": "Metformin AUC(0-inf)", "populationDescription": "All treated participants not discontinuing prior to end of study. 2 participants in Treatment A \\& 1 in Treatment B were excluded due to the inability to estimate with acceptable accuracy a terminal slope for terminal phase concentration data. Treatment C administered only during Period 3, and this outcome measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10336.18", "spread": "3066.13"}, {"groupId": "OG001", "value": "9211.29", "spread": "3364.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of a 5-mg saxagliptin tablet plus two 500-mg metformin XR tablets under fed conditions, then 24 subjects would have provided 99% power to conclude BE with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided at least 99% power to conclude BE with respect to Cmax and AUC0-inf.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within 0.800 to 1.250 for both Cmax and AUC0-inf of metformin.", "paramType": "ratio of geometric least squares means", "paramValue": "0.894", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.833", "ciUpperLimit": "0.959", "estimateComment": "Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares mean for Treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "8713.4", "ciPctValue": "95"}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares mean for Treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "9746.3", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Metformin AUC(0-t)", "populationDescription": "All treated participants not discontinuing prior to end of study. Treatment C was administered only during Period 3, and this outcome measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9734.38", "spread": "3123.76"}, {"groupId": "OG001", "value": "8846.36", "spread": "3304.75"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "ratio of geometric least squares means", "paramValue": "0.906", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.848", "ciUpperLimit": "0.968", "estimateComment": "Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares means for Treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "8377.8", "ciPctValue": "95"}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares mean for Treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric least squares mean (ng*hr/mL)", "paramValue": "9246.8", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Metformin AUC(0-tau)", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "9501.81", "spread": "4001.00"}]}]}]}, {"type": "PRIMARY", "title": "Metformin Cmax", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1184.07", "spread": "276.12"}, {"groupId": "OG001", "value": "1078.67", "spread": "221.72"}, {"groupId": "OG002", "value": "979.93", "spread": "267.58"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "If there was no difference between the bioavailabilities of metformin from the FDC tablet versus metformin from coadministration of a 5-mg saxagliptin tablet plus two 500-mg metformin XR tablets under fed conditions, then 24 subjects would have provided 99% power to conclude BE with respect to Cmax and AUC0-inf. If there was a 5% difference, then 24 subjects would have provided at least 99% power to conclude BE with respect to Cmax and AUC0-inf.", "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "BE was concluded if the 90% CIs for the test-to-reference ratios of geometric means were entirely contained within 0.800 to 1.250 for both Cmax and AUC0-inf of metformin.", "paramType": "ratio of geometric least squares means", "paramValue": "0.917", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.859", "ciUpperLimit": "0.980", "estimateComment": "Ratio = Treatment B/Treatment A. Geometric least squares means values are presented in other statistical analysis entries."}, {"groupIds": ["OG001"], "groupDescription": "Geometric least squares means for Treatment B", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "1055.9", "ciPctValue": "95"}, {"groupIds": ["OG000"], "groupDescription": "Geometric least squares means for Treatment A", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Geometric Least Squares Mean (ng*hr/mL)", "paramValue": "1151.2", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Metformin Cmin", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "105.04", "spread": "88.09"}]}]}]}, {"type": "SECONDARY", "title": "Metformin Cavg", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "395.91", "spread": "166.71"}]}]}]}, {"type": "SECONDARY", "title": "Metformin Fluctuation %", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of fluctuation", "timeFrame": "Period 3: predosing on Days 2 and 3; predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, and 24 hours postdosing on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG002", "value": "240.06", "spread": "73.54"}]}]}]}, {"type": "SECONDARY", "title": "Metformin T1/2", "populationDescription": "All treated participants not discontinuing prior to the end of study. One participant in Treatment A was excluded as a result of the inability to estimate with acceptable accuracy a terminal slope for the terminal phase concentration data. Treatment C was administered only during Period 3, and this outcome measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng*hr/mL", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.02", "spread": "6.15"}, {"groupId": "OG001", "value": "12.94", "spread": "6.74"}]}]}]}, {"type": "SECONDARY", "title": "Metformin AUC(0-inf) Contributed by AUC(0-t)(AUC[0-t]/AUC[0-inf])", "populationDescription": "All treated participants not discontinuing prior to end of study. 2 participants in Treatment A \\& 1 in Treatment B were excluded as a result of the inability to estimate with acceptable accuracy a terminal slope for terminal phase concentration data. Treatment C was administered only during Period 3, \\& this measure was analyzed for Periods 1 and 2.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "Periods 1 and 2: predosing, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36 and 48 hours postdosing.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.967", "spread": "0.029"}, {"groupId": "OG001", "value": "0.963", "spread": "0.034"}]}]}]}, {"type": "SECONDARY", "title": "Metformin Tmax", "populationDescription": "All treated participants not discontinuing prior to end of study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "hour", "timeFrame": "Periods 1 & 2:predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24, 36, 48 hours postdose. Period 3: predose on Days 2 & 3; predose, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 18, 24 hours postdose on Day 4.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.38", "spread": "0.73"}, {"groupId": "OG001", "value": "4.84", "spread": "0.91"}, {"groupId": "OG002", "value": "5.00", "spread": "1.30"}]}]}]}, {"type": "SECONDARY", "title": "Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs)", "description": "AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.", "populationDescription": "All subjects who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "AEs: from initiation of study drug administration on morning of Day 1/Period 1 through study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or participation in study if last scheduled visit occurred later.", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"title": "Number of Participants With At Least 1 AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Discontinuation Due to AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities", "description": "Abnormalities considered clinically significant and/or reported as an AE by the investigator.", "populationDescription": "All subjects who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "From Day 1 of Period 1 to Day 3 of Period 2 for participants in Treatment Sequence BA and Day 5 of Period 3 for participants in Treatment Sequence ABC", "groups": [{"id": "OG000", "title": "Treatment A", "description": "Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions"}, {"id": "OG001", "title": "Treatment B", "description": "Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions"}, {"id": "OG002", "title": "Treatment C", "description": "Treatment C: FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "14"}]}], "classes": [{"title": "Clinical Laboratory Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Vital Sign Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Physical Examination Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "12-Lead ECG Abnormalities", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "eventGroups": [{"id": "EG000", "title": "Saxa 5mg + 2x500mg Metformin, Fed", "description": "5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions", "seriousNumAffected": 0, "seriousNumAtRisk": 29, "otherNumAffected": 3, "otherNumAtRisk": 29}, {"id": "EG001", "title": "Saxa 5mg/1000mg Metformin, Fed", "description": "Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions", "seriousNumAffected": 0, "seriousNumAtRisk": 30, "otherNumAffected": 3, "otherNumAtRisk": 30}, {"id": "EG002", "title": "Saxa 5mg/500mg Metformin, Fed 4 Days", "description": "FDC tablet (5 mg saxagliptin + 1000 mg metformin XR), once daily for 4 days, under fed conditions.", "seriousNumAffected": 0, "seriousNumAtRisk": 14, "otherNumAffected": 4, "otherNumAtRisk": 14}], "otherEvents": [{"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "DIZZINESS", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "DRY MOUTH", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "TOOTHACHE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "CONSTIPATION", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "ABDOMINAL PAIN", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "APHTHOUS STOMATITIS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "ABDOMINAL DISTENSION", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "GASTROENTERITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 14}]}, {"term": "DYSURIA", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 14}]}, {"term": "ACNE", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "VAGINAL DISCHARGE", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "VULVOVAGINAL PRURITUS", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}, {"term": "PAIN IN EXTREMITY", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 29}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 30}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 14}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Game", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}